Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking To Generate Sizable License Revenue From IP Growth, Expanding Patent Suite

(MENAFN- Investor Brand Network)

  • Lexaria, a global innovator in drug delivery platforms, has, since 2014, continuously worked on its patented DehydraTECH(TM) drug delivery technology
  • The technology has demonstrated overall effectiveness in enhanced delivery of fat-soluble molecules through the human gastrointestinal system, as affirmed by clinical testing
  • This overall effectiveness and push for its development has earned Lexaria 37 granted patents globally, with many patents pending
  • The company is constantly enhancing its patent portfolio, since granted patents can support an increase in licensing revenue

Lexaria Bioscience (NASDAQ: LEXX) , a global innovator in drug delivery platforms, is eyeing growth in license revenue from its intellectual property (“IP”). Since 2014, the company has continuously worked on its flagship technology – the patented DehydraTECH(TM) drug delivery technology – which has demonstrated the improvement of speed of onset, brain absorption, and bioavailability ( ).
It is being investigated in association with dementia treatment, nicotine replacement, hypertension, and heart disease treatment, among other applications ( ).

So far, Lexaria has received 37 granted patents globally, with many patents pending. The company is aggressively pushing its patent application process as it recognizes the viable commercial application of its flagship technology. In addition, the company understands that successfully granted patents can lead...

Read More>>

The latest news and updates relating to LEXX are available in the company's newsroom at

About CBDWire

(“CBDW”) is a specialized communications platform with a focus on CBD related news and updates in the cannabidiol (“CBD”) sector. It is one of 60+ brands within
Dynamic Brand Portfolio
that delivers :
(1) access to a vast network of wire solutions via
to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ;
(2) article and
editorial syndication to 5,000+ outlets ;
(3) enhanced
press release enhancement
to ensure maximum impact ;
social media distribution
via IBN to millions of social media followers ;
and (5) a full array of tailored
corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, CBDW brings its clients unparalleled recognition and brand awareness.

CBDW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CBDWire, text“CBDWire” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published:

Denver, CO

303.498.7722 Office

CBDWire is powered by


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.